Abstract
Simulation models are a powerful tool to overcome gaps of evidence needed to inform medical decision making. Here, we present development and application of a multistate Markov model to simulate effects of colorectal cancer (CRC) screening, along with a thorough assessment of the model’s ability to reproduce real-life outcomes. Firstly, we provide a comprehensive documentation of the model development, structure and assumptions. Secondly, to assess the model’s external validity, we compared model-derived cumulative incidence and prevalences of colorectal neoplasms to (1) results from KolosSal, a study in German screening colonoscopy participants, (2) registry-based estimates of CRC incidence in Germany, and (3) outcome patterns of randomized sigmoidoscopy screening studies. We found that (1) more than 90% of observed prevalences in the KolosSal study were within the 95% confidence intervals of the model-predicted neoplasm prevalences; (2) the 15-year cumulative CRC incidences estimated by simulations for the German population deviated by 0.0-0.2 percent units in men and 0.0-0.3 percent units in women when compared to corresponding registry-derived estimates; and (3) the time course of cumulative CRC incidence and mortality in the modelled intervention group and control group closely resembles the time course reported from sigmoidoscopy screening trials. Summarized, our model adequately predicted colorectal neoplasm prevalences and incidences in a German population for up to 25 years, with estimated patterns of the effect of screening colonoscopy resembling those seen in registry data and real-world studies. This suggests that the model may represent a valid tool to assess the comparative effectiveness of CRC screening strategies.
Novelty and Impact The best long-term strategy to screen for colorectal cancer is unknown. To overcome gaps of evidence in this context, we developed a simulation model and assessed its external validity. The model predicted the natural history of colorectal cancer for up to 25 years and was able to reproduce effects of screening seen in real-world data. Our model may be used as a transparent, valid tool to inform medical decision making on colorectal cancer screening strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Financial support for this study was provided in part by a grant by the German Federal Ministry of Education and Research (grant number 01GL1712). The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report. TH was supported by the Helmholtz International Graduate School for Cancer Research at the German Cancer Research Centre (DKFZ).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Categories: Innovative Tools and Methods; Cancer Epidemiology; Cancer Therapy and Prevention
Data Availability
All analyses relevant to the study are included in the article or uploaded as supplementary information. The R code defining the core model is uploaded as supplementary information. All data requests regarding the KolosSal study should be submitted to the corresponding author for consideration. Access to anonymised data may be granted following review.
Abbreviations
- ADN
- any advanced neoplasm
- ANN
- any neoplasm
- CI
- confidence interval
- CRC
- colorectal cancer
- ITT
- intention to treat
- KOLOSSAL
- Effektivität der Früherkennungs-Koloskopie: eine Saarland-weite Studie
- NORCCAP
- Norwegian Colorectal Cancer Prevention trial
- PLCO
- Prostate, Lung, Colorectal and Ovarian trial PP per protocol
- PRR
- prevalence ratio
- RCT
- randomized controlled trial
- SCORE
- Screening for Colon Rectum trial
- TOST
- two one-sided t-tests
- UKFSS
- United Kingdom Flexible Sigmoidoscopy Screening
